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Research
Maternal Serum Polychlorinated Biphenyl Concentrations across Critical
Windows of Human Development
Michael S. Bloom,1 Germaine M. Buck Louis,1 Enrique F. Schisterman,1 Aiyi Liu,2 and Paul J. Kostyniak3
1Epidemiology

Branch, and 2Biometry and Mathematical Statistics Branch, Division of Epidemiology, Statistics and Prevention Research,
National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services,
Bethesda, Maryland, USA; 3Department of Biotechnical and Clinical Laboratory Sciences, School of Medicine and Biomedical Sciences,
University at Buffalo, the State University of New York, Buffalo, New York, USA

BACKGROUND: Few data are available on polychlorinated biphenyl (PCB) concentrations over
critical windows of human reproduction and development inclusive of the periconception window.
OBJECTIVES: Our goal was to measure changes in PCB concentrations from preconception to
pregnancy, through pregnancy, or after a year without becoming pregnant.
METHODS: Seventy-nine women planning pregnancies were prospectively enrolled and followed for
up to 12 menstrual cycles of attempting pregnancy. Blood specimens were obtained from participating women preconceptionally (n = 79), after a positive pregnancy test leading to a live birth (n =
54) or pregnancy loss (n = 10), at approximately 6 weeks postpartum (n = 53), and after 12 unsuccessful cycles (n = 9) for toxicologic analysis of 76 PCB congeners. We estimated overall and daily
rate of change in PCB concentration (nanograms per gram serum) adjusting for relevant covariates,
serum lipids, and baseline PCB concentration.
RESULTS: Significant (p < 0.0001) decreases in the mean overall and daily rate of change in PCB
concentrations were observed between the preconception and first pregnancy samples for total
(–1.012 and –0.034, respectively), estrogenic (–0.444 and –0.016, respectively), and antiestrogenic
(–0.106 and –0.004, respectively) PCBs among women with live births. Similar significant
decreases in total (–1.452 and –0.085), estrogenic (–0.647 and –0.040), and antiestrogenic (–0.093
and –0.004) PCB concentrations were seen for women with pregnancy losses. No significant
changes were observed for PCB congener 153.
CONCLUSIONS: These data suggest that PCB concentrations may change during the periconception
interval, questioning the stability of persistent compounds during this critical window.
KEY WORDS: critical windows, infertility, periconception, persistent organic pollutants, polychlorinated biphenyls (PCBs), pregnancy loss. Environ Health Perspect 115:1320–1324 (2007).
doi:10.1289/ehp.10086 available via http://dx.doi.org/ [Online 9 July 2007]

The environmental persistence and lipophilicity of polychlorinated biphenyls (PCBs) in the
Great Lakes basin and elsewhere has lead to
bioaccumulation within the aquatic food chain
and human exposure (Ayotte et al. 1995;
Bloom et al. 2005; He et al. 2001). Dietary
PCB exposure has been associated with adverse
reproductive (Buck et al. 2000; Mendola et al.
2005) and developmental outcomes (Jacobson
and Jacobson 1997), underscoring the importance of exposures during critical or sensitive
windows (Morford et al. 2004).
Although past research has focused on
in utero PCB exposure for clinically recognized
pregnancies in relation to human development, only limited investigation of periconception exposures has been undertaken (Chapin
et al. 2004). This impairs our ability to accurately model the effects of pregnancy and/or
lactation in assessing reproductive outcomes
conditional on pregnancy. We assessed concentrations of PCB congeners from preconception through pregnancy and postpartum to
better understand their dynamics over critical
windows.

Materials and Methods
Study population and sample. We used a
prospective cohort design to recruit women
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from the New York State Angler Cohort Study
(NYSACS), a population-based cohort comprising licensed anglers 18–40 years of age who
were randomly selected from 16 contiguous
counties along Lakes Erie and Ontario (Vena
et al. 1996). The purpose of this prospective
pregnancy study with preconception enrollment was twofold: to obtain longitudinally
collected biospecimens for the quantification
of PCBs over sensitive critical windows, and to
evaluate periconception data collection
methodologies appropriate for populationbased epidemiologic research. The study protocol complied with the U.S. regulations on
the protection of human subjects; all study
participants gave written informed consent
before participation in any aspect of the study.
In 1996–1997, introductory recruitment
letters were mailed to 2,637 female participants in the NYSACS who had stated interest
in possibly becoming pregnant in 1995–1996.
After repeated telephone attempts, 1,031
(39%) women were successfully screened, of
whom 244 were eligible for participation—
defined as planning pregnancy in the next
6 months, age 18–34 years, and no physician
diagnosis of infertility. The study sample comprised 113 women (46%) who reported planning pregnancies within 6 months; however,
VOLUME

14 women were already pregnant and therefore excluded. The final study cohort comprised 99 women, of whom 20 withdrew over
the course of the 12 months of attempting
pregnancy. The distribution of reproductive
outcomes among participating women completing the study included 54 (68%) women
whose pregnancies resulted in live births, 10
(13%) women whose pregnancies ended in
early losses, 4 (5%) women whose pregnancies
ended after clinical recognition, and 11 (14%)
women who were unable to conceive within
12 menstrual cycles of trying.
Data collection. Participation required a
baseline interview, completion of a daily
diary, and provision of nonfasting blood specimens at baseline (preconception) and after a
positive home pregnancy test result or after
12 unsuccessful menstrual cycles without
pregnancy. For women giving birth, an additional blood specimen was obtained at approximately 6 weeks after delivery (postpartum).
The research nurse instructed women in the
proper use of home pregnancy kits reported to
be capable of detecting 50 mIU of human
chorionic gonadotropin (hCG).
Approximately 25 mL of blood yielding
approximately 10 mL of serum were obtained
as follows: from all 79 participating women at
baseline or preconception; from 54 women
after a positive pregnancy test resulting in a
live birth (prenatal); from 10 women after a
positive pregnancy test approximately 2 weeks
postimplantation that resulted in an early
pregnancy loss (EPL); from 4 women after a
positive pregnancy test resulting in a clinical
pregnancy loss (CPL); from 54 women
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approximately 6 weeks after a live delivery
(postnatal); and from 10 women after 12
unsuccessful menstrual cycles without pregnancy (infertile). Thus, we have a blood specimen reflecting the varying critical windows
(preconception, postimplantation, and postnatal) and reproductive outcomes (pregnancy
loss, live birth, infertility). The blood samples
were transported on ice to the toxicology laboratory; these included 73 (92%) baseline or
preconception, 53 (98%) prenatal, 10 (100%)
EPL, 3 (75%) CPL, 52 (96%) postnatal, and
9 (90%) infertility blood samples.
Toxicologic analysis. Serum samples were
mixed with solutions of International Union
of Pure and Applied Chemistry PCB isomers
no. 46 and 142 (surrogate standards) and left
overnight to equilibrate (Greizerstein et al.
1997). Methanol was added to precipitate the
proteins, and the resulting mixture was
extracted with hexane in a rotating extraction
device at 50 rpm for 20 hr. Samples were
then centrifuged and the extract was concentrated under a slow stream of nitrogen at
50° C to 2 mL. The extract was placed on a
deactivated Florisil column and eluted with
hexane. The eluate was evaporated to a small
volume under a slow stream on nitrogen using
200 µL iso-octane as a keep solvent. Isomers
no. 30 and 204 were added as internal standards to each extract. An aliquot of the mixture was injected into the gas chromatograph
equipped with an electron capture detector
(Agilent Technologies, Santa Clara, CA).
A quality control (QC) sample was made
from a matrix blank consisting of sheep
serum, which was spiked with 0.6 ng/g PCB
congeners 6, 44, and 52; 0.3 ng congeners
101, 138, 153, 180, 185, and 205; and 0.3 ng
pesticides dichlorodiphenyldichloroethylene,
hexachlorobenzene, and mirex. The QC sample was run with each batch of 10 samples and
appropriate reagent and matrix blanks.
Quality control charts were kept throughout
the study and any batch of samples in which
the QC values exceeded acceptance criteria
were rerun. Surrogate congener standards 46
and 142 were added to each sample to assess
recoveries. The surrogate standard recoveries
for one set of 500 serum samples was 85.5 ±
18.6% for PCB-46 and 83.1 ± 16.4% for
PCB-142. Serum specimens were run in
batches of 10 plus four quality control samples: reagent blank, matrix blank, matrix blank
containing a mixed standard of 15 specific
congeners and pesticide components at known
values, and a duplicate participant sample.
The laboratory is in compliance in the AMAP
Ring Test Proficiency Program for Persistent
Organic Pollutants in Human Serum (Centre
de toxicologie Institut national de santé
publique du Québec, Québec, Canada).
We corrected laboratory observed values
only for recovery to minimize measurement
Environmental Health Perspectives

error and potential biases associated with substitution patterns below the limits of detection (LOD) (Richardson and Ciampi 2003;
Schisterman et al. 2006). A priori, 64 singleeluting and 12 di-eluting congeners were
quantified and summed into three groupings
(Cooke et al. 2001): a) total PCB congeners;
b) estrogenic congeners (4 + 10, 8 + 5, 15 +
17, 18, 31, 44, 47, 48, 52, 70, 77 + 110, 99,
101, 126, 136, 153, and 188); and c) antiestrogenic congeners (77 + 110, 105, 114,
118, 126, 156 + 171, and 169). We assessed
PCB congener 153 individually for comparison with other work focusing on female
fecundity (Axmon et al. 2001). We also
assessed PCB-118 individually given that
most concentrations were above the LOD,
similar to PCB-153, and to aid in the interpretation of results by PCB grouping. We
quantified total serum lipids (TL) using enzymatic methods as the function of total cholesterol (TC) and triglycerides (TG) expressed in
milligrams per deciliter. We assumed free
cholesterol to be 27% of the total, and predicted phospholipids from regression on total
cholesterol where TL = 2.27 TC + TG +
0.623 (Phillips et al. 1989). For analysis purposes, PCB concentrations are reported as
nanograms per gram wet weight with serum
lipids entered as a covariate in the analytic
model to minimize bias arising from automatic lipid adjustment of PCB concentrations
(Schisterman et al. 2005).
Statistical analysis. With descriptive statistics, many PCB congener distributions were
not normally distributed even after Box-Cox
transformations; therefore, no further transformations were undertaken. We used bivariate
analysis to explore associations between the
changes in concentrations from the baseline or
preconception to the next serum measurement
in relation to serum lipids (milligrams per
deciliter) and relevant study covariates—i.e.,
body mass index (weight in kilograms/height
in square meters), gravidity (number of pregnancies), parity (number of births), and lifetime duration of lactation in months (Glynn
et al. 2003; Grimvall et al. 1997; Kostyniak
et al. 1999; Sweeney et al. 2001).
We estimated Spearman rank correlation
coefficients to describe correlations between
baseline PCB groupings, and between the
measurements across critical windows. For
each correlation, we used the chi-square test to
obtain the level of significance against the null
(zero correlation), using Fisher’s z-transformation [z = 0.5 log(1 + r)/(1 – r)] with the
appropriate variance correction.
We estimated the overall amount of
change between measurements and the daily
rate of change in serum PCB concentrations
and total serum lipids for 48 paired preconception-prenatal specimens, 47 paired
prenatal–postnatal specimens, 10 paired
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preconception–EPL specimens, and 9 paired
preconception–infertility specimens, using the
following algorithm:
Dijk = Y ijk − Y ijk′ ,

[1]

where Y ijk represents measures for the ith
(1,……,n) participant; for the jth PCB grouping (where 1 = total PCBs, 2 = estrogenic
PCBs, 3 = antiestrogenic PCBs, 4 = PCB-118,
5 = PCB-153, and 6 = total serum lipids variable, respectively); demonstrating the kth (1,
2, 3, 4) reproductive outcome (where 1 = prenatal or a pregnancy resulting in a live birth, 2
= EPL or a pregnancy resulting in an early
loss, 3 = infertile or 12 menstrual cycles without conception, and 4 = postnatal after a live
´ represents the baseline or prebirth; and Yijk
conception measurement for k = 1, 2, or 3,
and the prenatal measurement from a pregnancy resulting in a live birth where k = 4.
Women’s daily rate of change, defined as
the difference in the concentration between
the first (baseline) and second specimen collection divided by the number of days between
specimen collections, was derived as follows:
Rijk = Dijk t i ,

[2]

where ti represents the duration in days, for the
ith (1,…,n) participant, between the reported
positive hCG pregnancy test date and the outcome specimen sample date, where k = 1, 2,
between the dates of the baseline and outcome
specimens where k = 3, and the date of the prenatal and postnatal specimens where k = 4. We
assumed no change in PCB concentration
between the date of baseline measure and the
date of the positive hCG test among those
women who conceived. We further estimated
the daily rates of change in concentrations
from the time of the positive pregnancy test to
the second blood specimen. Length of gestation at the time of the prenatal sample ranged
from 8 to 126 days with a mean (± SD) of
31.4 ± 17.5 days and a median of 29 days.
We estimated the mean overall and daily
rate of change in PCB concentration using
multiple linear regression, adjusting for
preconception PCB concentration and lipids,
centering each by its mean to facilitate interpretation of model intercepts as the change in
PCBs at the average lipid and baseline PCB
concentrations. Estimating the difference in
PCBs’ grouping concentrations between the
two measurements simplified the variance
structure by removing part of the correlation
between observations on the same woman.
Additional covariates were not included in
models given the absence of significance, nor
were separate models run for the three clinical
pregnancy losses. Serum lipids could
not be quantified for 10 women (8 live
births, 1 pregnancy loss, and 1 infertile) given
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insufficient sample necessitating expectation
maximization (Yuan 2000).
We evaluated the normality assumption
for each regression model by examining residuals employing Q–Q plots and by comparing
predicted values with those generated employing the LOESS nonparametric regression

procedure, because changes in PCB concentrations deviated substantially from normality
even with transformation. Significance was
defined as p < 0.05 for two-tailed tests; crude
differences in overall change and daily rate of
change in PCB concentration were evaluated
using the Wilcoxon signed rank test.

Table 1. Description of study cohort at baseline by reproductive outcome [median (range)].
Prenatal (n = 48)

Characteristic

Pregnancy loss (n = 10)

PCBs (ng/g serum)
Total PCBs
5.27 (3.66–12.68)
Estrogenic PCBs
2.29 (1.66–3.77)
Antiestrogenic PCBs
0.20 (0.03–0.65)
PCB-118
0.09 (0.01–0.31)
PCB-153
0.26 (0.10–1.24)
Total serum lipids
530.17 (357.57–915.38)
(mg/dL)
Age (years)
30.5 (26–34)
BMI (kg/m2)
22.18 (17.7–39.9)
Gravidity (no. of pregnancies)
1 (0–5)
Parity (no. of births)
1 (0–3)
Breast-feeding
6.0 (1–28)
(no. of months)a

Infertility (n = 9)

5.21 (3.89–9.09)
2.29 (1.78–4.54)
0.18 (0.03–0.33)
0.12 (0.02–0.16)
0.25 (0.16–0.47)
529.05 (307.91–829.94)

4.62 (4.10–7.19)
2.09 (1.79–3.18)
0.22 (0.12–0.29)
0.08 (0.05–0.21)
0.24 (0.15–0.55)
475.39 (414.45–723.67)

29.5 (26–33)
22.39 (17.54–34.56)
1 (0–3)
1 (0–3)
10.5 (2–13)

30.0 (26–32)
21.46 (17.28–31.15)
0.5 (0–2)
0 (0–2)
13.0 (6–20)

BMI, body mass index. None of the above differences achieved statistical significance. Reproductive outcome refers to
the timing of the second blood collection.
aRestricted to the 39 women reporting a history of breast-feeding at baseline.

Table 2. Spearman correlation coefficients among baseline PCB groupings (n = 67).
PCB grouping

Total PCBs

Total
Estrogenic
Antiestrogenic
PCB-118
PCB-153

1.000

Estrogenic PCBs

Antiestrogenic PCBs

0.938**
1.000

PCB-118

0.494**
0.343*
1.000

PCB 153

0.341*
0.258*
0.799**
1.000

0.600**
0.499**
0.629**
0.418*
1.000

*p < 0.05; **p < 0.0001.

Table 3. Spearman correlation coefficients among paired biospecimens by PCB grouping and critical
window.

PCB grouping
Total PCBs
Estrogenic PCBs
Antiestrogenic PCBs
PCB-118
PCB-153

Baseline
measure with
prenatal (n = 48)
0.328*
0.168
0.558**
0.755**
0.513*

Baseline
measure with
early loss (n = 10)

Baseline
measure with
infertility (n = 9)

Prenatal
measure with
postnatal (n = 47)

0.317
0.383
0.467
0.300
0.567

–0.265
–0.346*
0.095
0.281
0.320*

0.745*
0.588
0.394
0.770*
0.770*

*p < 0.05; **p < 0.0001.

Table 4. Mean adjusted overall and daily rates of change in serum PCB concentrations, by PCB groupings
and reproductive outcome.
PCB grouping
Overall change
(ng/g serum)

Daily rate of change
(ng/g serum)

Total PCBs
Estrogenic PCBs
Antiestrogenic PCBs
PCB-118
PCB-153
Total PCBs
Estrogenic PCBs
Antiestrogenic PCBs
PCB-118
PCB-153

Prenatala
(n = 48)
–1.012**
–0.444**
–0.106**
–0.016
–0.021
–0.034**
–0.016**
–0.004**
–0.001*
–0.000

Pregnancy lossa
(n = 10)
–1.452**
–0.647**
–0.093*
–0.014
–0.041
–0.085**
–0.040**
–0.004#
–0.001
–0.003

Infertilitya Prenatal to postnatalb
(n = 9)
(n = 47)
–0.281
–0.312
0.065
0.010
–0.015
–0.000
–0.001
0.000
0.000
–0.000

aAdjusted

1.938*
0.628*
0.228*
0.023
0.016
0.008*
0.003*
0.001*
0.000##
0.000##

for overall change (mg/dL serum) or daily rate of change (mg/dL serum) in total serum lipids and baseline PCB
concentration (ng/g serum). bAdjusted for overall change or daily rate of change in total serum lipids (mg/dL), prenatal
PCB concentration and duration of breast-feeding between delivery and the postnatal sample. *p ≤ 0.004; **p < 0.0001;
#p = 0.03. ##Observed values were 0.000115 and 0.000053, respectively, but rounded to zero.
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Results
We observed no significant differences in the
median preconception PCB concentrations by
PCB grouping and reproductive outcome or for
any of the other study covariates (Table 1). The
median interval between the timing of the two
serum PCB measurements was 63 days
[interquartile range (IQR) = 34] for early pregnancy loss, 79 days (IQR = 76) for clinical
pregnancy loss, 151 days (IQR = 180.5) for live
birth, 446 days (IQR = 127) for infertility, and
240 days (IQR = 21) for the pre- and postnatal.
Baseline PCB groupings were significantly correlated with each other (Table 2).
Significant correlations were found between
baseline and prenatal measures for all PCB
groupings except estrogenic PCBs, between
baseline and early pregnancy loss measures for
total PCBs, PCB-118 and PCB-153, and
between pre- and postnatal samples for estrogenic PCBs and PCB-153 (Table 3).
Table 4 presents the adjusted regression
models for overall and daily rate of change in
concentrations by PCB grouping and reproductive outcome. p-Values are presented in lieu
of 95% confidence intervals to avoid the use of
negative exponents, though the latter are available on request. Significant mean overall and
daily rates of change in PCB concentrations
(nanograms per gram serum) were consistently
observed for women becoming pregnant
regardless of outcome for total, estrogenic, and
antiestrogenic groupings. Results for the infertile women were inconsistent (positive and
negative) and none were significant. Of particular note is the absence of any overall or daily
changes in concentrations for PCB-153 regardless of reproductive outcome, in contrast to an
observed significant change (–0.001) for daily
PCB-118 among women giving birth. Overall
mean PCB concentrations (nanograms per
gram serum) adjusted for duration of breastfeeding (reported by 34 women) significantly
increased in women from prenatal to postnatal
measurement for total (1.938), estrogenic
(0.628), and antiestrogenic PCBs (0.228) as
did the daily rate of change—0.008, 0.003,
and 0.001, respectively. Median serum lipids
(expressed in milligrams per deciliter) declined
15.97 (range –282.89 to 261.29) from preconception to prenatal for women whose pregnancies resulted in a birth, and 1.57 (range
–144.71 to 105.96) for women experiencing
losses, but increased 18.97 (range –53.78 to
137.68) for infertile women. None of these
results achieved significance (data not shown).
Overall and daily rates of change in serum
lipids were not significant predictors of changes
in PCB concentrations (data not shown),
except for the daily rate of change in antiestrogenic PCBs between preconception and
the prenatal blood and between the preconception and EPL measurements (i.e., β = 0.0004
and β = 0.0009, respectively; p = 0.02).
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Discussion
This prospective pregnancy study with preconception enrollment of women is the first to
demonstrate the possible instability of PCB
concentrations over critical windows such as
conception and implantation, as measured by
hCG-detected pregnancy. Our findings suggest that both the overall and daily rate of
change in serum PCB concentrations may be
associated with reproductive outcome, though
cautious interpretation is needed given the
limited cohort size and reliance on only two
measurements. Further supporting these
observations is the lack of change in concentrations for women who failed to achieve an
hCG-confirmed pregnancy within 12 menstrual cycles, though admittedly with a limited
number of women. To this end, use of preconception cohorts with ascertainment of all
women regardless of reproductive outcomes is
essential for understanding exposure profiles
relevant for the assessment of time-dependent
health effects. Last, our study findings
remained consistent regardless of PCB grouping suggesting that categorization did not
drive our results. In the absence of a universally accepted classification scheme for the
assessment of human health effects, our a priori classification allowed us to formalize our
assumptions when characterizing the cohort’s
exposure over time.
The reasons for the early changes between
preconception and hCG-detected pregnancy
are unknown and somewhat puzzling given the
alleged persistence of these chemicals in the
body. We speculate that early homeostatic
changes after human conception and early
embryonic development may affect chemical
mobilization from lipid reserves, possibly as a
result of the many physiologic changes accompanying pregnancy (Bernstein et al. 2001) that
may affect the absorption, distribution, metabolism, and excretion of exogenous compounds
(Casarett et al. 1996). Another possible interpretation is laboratory noise given the observed
distribution of concentrations including values
below the LOD [Appendix 1, Supplemental
Material (online at http://www.ehponline.
org/docs/2007/10086/suppl.pdf)]. We do not
believe that this potential source of bias
accounts for our findings, given our use of
observed values as previously discussed.
Environmental Health Perspectives

Regardless of the underlying mechanisms,
these findings underscore the potential for
variability arising from epidemiologic studies
that rely on a single blood measurement of
exposure, especially if captured at varying
times during pregnancy or if relying only on
women with clinically viable pregnancies. The
utility and feasibility of prospective pregnancy
studies with preconception enrollment of
women or couples has been discussed previously (Buck et al. 2004). In essence, pregnancy loss may be viewed as a competing risk
for birth if higher exposures or exposures during critical windows systematically are associated with pregnancy outcome. Bias also may
arise from collider stratification (Hernan et al.
2004) that may arise when an intermediate
variable such as reproductive outcome is used
to stratify the analysis. Because reproductive
outcome could be directly affected by two or
more other unmeasured variables, stratifying
on it can generate spurious study findings.
However, it is unlikely that this type of bias
would explain the large differences observed
in our study. Still, we recognize the need for
the results to be interpreted within the context of this validity threat. Our results discourage continued reliance on a single PCB
congener such as PCB-153 for assessing the
reproductive or developmental toxicity of all
PCBs or other persistent compounds in the
absence of further empirical assessment.

We are unaware of any prospective pregnancy studies with preconception enrollment
that quantified serum PCBs concentrations
across critical windows. To this end, we believe
our longitudinal cohort study is the first to provide empirical data regarding mean changes in
serum concentrations of PCBs from the preconception-to-postnatal window of human
development. A few previous investigators have
assessed the stability of select PCB congeners
across trimesters of clinically established pregnancies and reported them to be highly correlated (Longnecker et al. 1999), as do
investigators comparing maternal concentrations during established clinical pregnancies
with cord or postnatal concentrations (Ayotte
et al. 2003; Jarrell et al. 2005). However, such
correlation coefficients cannot be adjusted for
time intervals or other relevant covariates. The
median prenatal total PCB concentration for
the 48 women giving birth in our study is comparable to that for the 67 first trimester women
in the study by Longnecker et al. (1999), suggesting similarity in study cohorts with regard
to exposure status (4.5 ng/g serum and
4.4 µg/L serum, assuming nanograms per gram
≈ micrograms per liter ≈ parts per billion).
Of added note is the capture of all hCG
pregnancies in our study with the use of home
pregnancy test kits and women failing to
conceive along with clinical pregnancies.
A priori, we were interested in obtaining both

0.15
Live birth (n = 48)
Early pregnancy loss (n = 10)
× Infertility (n = 9)

0.10

Daily rate of change in total PCBs (ng/g serum by day)

Figure 1 illustrates the daily rate of change
in total PCBs by reproductive outcome as a
function of women’s baseline concentrations.
The dependence of daily rate of change on
baseline concentration is illustrated underscoring the need to adjust for baseline concentration when estimating the mean daily
rate of change. This finding supports the use
of summary statistics beyond simple correlations to allow simultaneous modeling of
important covariates.

0.05

0.00

–0.05

–0.10

–0.15
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Centered baseline total PCBs (ng/g serum)

Figure 1. Daily rate of change in total PCB concentrations as a function of baseline PCB concentrations.
Solid line, linear regression best fit line for live delivery group; dashed line, linear regression best fit line
for early loss group; dotted line, linear regression best fit line for infertile group.
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pre- and postconception biospecimens with an
additional biospecimen after an untoward
reproductive outcome or birth for fertile
women. Thus, we had only one blood sample
obtained during pregnancy. We also recognize
that some pregnancies may have been undetected by home pregnancy tests, possibly
resulting in women being misclassified as
infertile, despite the absence of significant differences in baseline concentrations by reproductive outcome. Not all women’s blood
specimens could be precisely collected on the
same day, given that women resided in 16
counties in New York State with a single
research nurse available for home blood collection. Timing of the second sample also
depended on the woman’s compliance with
home pregnancy testing and her ability to
accurately recognize and report a positive test.
Given the educational attainment of the
women coupled with instruction by the nurse
with regard to fertility awareness and the
proper use of home pregnancy test results,
pregnancy recognition bias is not likely to
have affected the timing of the test. Our
analyses do consider the interval (in days)
between our measurements. We decided
a priori not to correct for multiple comparisons given the exploratory nature of this work
and our intent to try to globally assess patterns
within and between PCB groupings and by
reproductive outcomes. Finally, we remain
uncertain about how best to model the chemical mixtures more representative of women’s
actual exposures. Our initial attempt to
categorize PCB congeners in an a priori manner should be viewed as preliminary and needing further refinement as our understanding of
the biological activity and underlying mechanisms evolves for this class of compounds.

Conclusions
In sum, PCB concentrations declined significantly during the periconception window of
human development among women achieving pregnancy. PCB concentrations increased
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among women with postnatal measurement.
These findings suggest a relatively dynamic
nature of serum PCB concentrations during
the earliest windows of human development,
underscoring the need to characterize exposures during the periconception window.
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